Myst Therapeutics, Inc.

Myst Therapeutics, Inc. is a biotechnology firm focused on pioneering gene therapies that treat a variety of genetic disorders, utilizing advanced gene editing techniques to create targeted molecular interventions. Founded in 2019 and headquartered in Los Angeles, US, Myst Therapeutics, Inc. specializes in innovative gene therapies.

The company was acquired by Turnstone Biologics Inc. in January 2021, although the financial terms of the acquisition were not disclosed. The firm has completed a total of one deal to date. Myst Therapeutics specializes in innovative gene therapies aimed at treating a range of genetic disorders.

The company’s core product offerings include proprietary therapeutic platforms that leverage advanced gene editing technologies to target specific genetic mutations. These therapies are designed to address unmet medical needs in various therapeutic areas, including rare diseases and certain types of cancers. Mystic Therapeutics primarily serves hospitals, specialty clinics, and research institutions in North America and Europe, focusing on end-users such as patients suffering from chronic and inherited conditions. Their product suite is continually evolving as they advance their research and development initiatives.

Myst Therapeutics generates revenue through structured partnerships and direct sales of its gene therapy products. The company engages in B2B transactions with healthcare providers and research institutions that incorporate their therapies into clinical settings. Revenue is derived from a combination of upfront payments associated with licensing agreements, milestone payments during the development phase, and royalties on eventual sales of products once they reach the market. Each therapy is associated with specific pricing plans tailored to the contractual agreements with clients, reflecting the significant investment in research and development required for such advanced therapies.

The firm strategically collaborates with various stakeholders to enhance the accessibility of its flagship products within diverse healthcare markets, thereby ensuring a sustainable revenue stream as they expand their reach. Myst Therapeutics plans to utilize the recent acquisition by Turnstone Biologics Inc. to support its growth strategy, focusing on advancing its gene therapy products and expanding into new healthcare markets. The company is expected to design and launch new therapies, with a commitment to addressing ongoing research needs in genetic disorders.

Specific details regarding upcoming products and their release dates are not disclosed, but the firm is poised to enhance its market presence by targeting additional healthcare providers and research institutions in North America and Europe by the end of 2023.